ATE534382T1 - Pharmazeutische zusammensetzungen von mit zuckeralkoholen zusammen mikronisiertem entacapon - Google Patents

Pharmazeutische zusammensetzungen von mit zuckeralkoholen zusammen mikronisiertem entacapon

Info

Publication number
ATE534382T1
ATE534382T1 AT09708991T AT09708991T ATE534382T1 AT E534382 T1 ATE534382 T1 AT E534382T1 AT 09708991 T AT09708991 T AT 09708991T AT 09708991 T AT09708991 T AT 09708991T AT E534382 T1 ATE534382 T1 AT E534382T1
Authority
AT
Austria
Prior art keywords
entacapone
sugar alcohols
micronized
pharmaceutical compositions
relates
Prior art date
Application number
AT09708991T
Other languages
English (en)
Inventor
Ritesh Kapoor
Sanjay Mate
Munish Talwar
Girish Kumar Jain
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Application granted granted Critical
Publication of ATE534382T1 publication Critical patent/ATE534382T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT09708991T 2008-02-06 2009-02-06 Pharmazeutische zusammensetzungen von mit zuckeralkoholen zusammen mikronisiertem entacapon ATE534382T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN264MU2008 2008-02-06
PCT/IB2009/050490 WO2009098663A1 (en) 2008-02-06 2009-02-06 Pharmaceutical compositions of entacapone co-micronized with sugar alcohols

Publications (1)

Publication Number Publication Date
ATE534382T1 true ATE534382T1 (de) 2011-12-15

Family

ID=40626966

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09708991T ATE534382T1 (de) 2008-02-06 2009-02-06 Pharmazeutische zusammensetzungen von mit zuckeralkoholen zusammen mikronisiertem entacapon

Country Status (20)

Country Link
US (1) US8728517B2 (de)
EP (1) EP2293791B1 (de)
JP (1) JP5651478B2 (de)
KR (1) KR101532810B1 (de)
CN (1) CN101939002B (de)
AT (1) ATE534382T1 (de)
AU (1) AU2009211030B2 (de)
BR (1) BRPI0907727A2 (de)
CA (1) CA2714113C (de)
CY (1) CY1116484T1 (de)
DK (1) DK2293791T3 (de)
ES (1) ES2377597T3 (de)
HR (1) HRP20120106T1 (de)
MX (1) MX2010008707A (de)
NZ (1) NZ587169A (de)
PL (1) PL2293791T3 (de)
PT (1) PT2293791E (de)
RU (1) RU2010136934A (de)
SI (1) SI2293791T1 (de)
WO (1) WO2009098663A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010023828A1 (de) * 2010-06-15 2011-12-15 IIP - Institut für industrielle Pharmazie, Forschungs- und Entwicklungsgesellschaft mbH Pharmazeutisches Präparat, welches Entacapon, Levodopa und Carbidopa enthält
CN106880607A (zh) * 2015-12-15 2017-06-23 北大方正集团有限公司 一种含有瑞戈非尼的口腔崩解片及其制备方法
CN115715767B (zh) * 2022-11-02 2023-06-09 石家庄四药有限公司 一种恩他卡朋片剂的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US6599530B2 (en) * 1998-09-14 2003-07-29 Orion Corporation Oral compacted composition comprising catechol derivatives
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
CA2611114C (en) * 2005-06-08 2014-09-23 Orion Corporation An entacapone-containing oral dosage form
GB2429645A (en) * 2006-03-10 2007-03-07 Sekhsaria Chemicals Ltd Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent

Also Published As

Publication number Publication date
NZ587169A (en) 2011-03-31
AU2009211030B2 (en) 2013-12-05
ES2377597T3 (es) 2012-03-29
JP5651478B2 (ja) 2015-01-14
AU2009211030A1 (en) 2009-08-13
EP2293791B1 (de) 2011-11-23
DK2293791T3 (da) 2012-02-13
JP2011526241A (ja) 2011-10-06
CY1116484T1 (el) 2017-03-15
CA2714113C (en) 2015-11-24
EP2293791A1 (de) 2011-03-16
BRPI0907727A2 (pt) 2017-06-13
CN101939002B (zh) 2012-12-26
SI2293791T1 (sl) 2012-03-30
CN101939002A (zh) 2011-01-05
US20110052681A1 (en) 2011-03-03
PL2293791T3 (pl) 2012-04-30
PT2293791E (pt) 2012-01-11
HRP20120106T1 (hr) 2012-02-29
MX2010008707A (es) 2011-03-25
CA2714113A1 (en) 2009-08-13
US8728517B2 (en) 2014-05-20
KR20100117096A (ko) 2010-11-02
WO2009098663A1 (en) 2009-08-13
KR101532810B1 (ko) 2015-06-30
RU2010136934A (ru) 2012-03-20

Similar Documents

Publication Publication Date Title
ATE510537T1 (de) Pharmazeutische zusammensetzungen von entacapon, levodopa und carbidopa mit verbesserter bioverfügbarkeit
ECSP13012668A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
EA201500650A1 (ru) Фенилацетат l-орнитина и способы его получения
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
GT201200250A (es) Ariltriazolonas ligadas a bisarilo y su uso
EA201101190A1 (ru) Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201100503A1 (ru) Глюкозидные производные и их применения
CU24037B1 (es) Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
UY31228A1 (es) Ariloxazoles sustituidos y su uso
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
UA105229C2 (uk) Фармацевтичний склад
CL2008000981A1 (es) Compuestos derivados de imidazolidin-carboxamida; composicion farmaceutica; procedimiento de produccion de la composicion farmaceutica; y uso en el tratamiento y/o prevencion de trastornos ateroscleroticos, de metabolismo de acidos grasos y en los qu
PA8794401A1 (es) Acidos 6-fenilnicotinicos sustituidos y su uso
ECSP11011082A (es) Compuestos, composición farmaceutica y métodos para utilizarse en el tratamiento de desórdenes metabólicos
ECSP088689A (es) NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS
EP3228311A3 (de) Pharmazeutische und nährstoffzusammensetzungen aus abscisinsäure
SV2007002235A (es) Nuevos derivados de pirimidina y su uso ref. bhc041311-sv
EA200901237A1 (ru) Применение димирацетама при лечении хронической боли
EA201071183A1 (ru) Безводная кристаллическая форма малеата орвепитанта
CL2011001777A1 (es) Composicion farmaceutica que contiene aleglitazar; proceso para preparar dicha composicion farmaceutica; y su uso para el tratamiento o profilaxis de la diabetes tipo ii o enfermedades cardiovasculares.
ATE534382T1 (de) Pharmazeutische zusammensetzungen von mit zuckeralkoholen zusammen mikronisiertem entacapon
WO2007121545A8 (en) S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2293791

Country of ref document: EP